By Mauro Orru

Merck KGaA said Thursday that it is acquiring AmpTec in a move to bolster its capabilities to develop and manufacture mRNA gene-based technology for vaccines, treatments and diagnostics.

AmpTec is a Hamburg, Germany-based mRNA contract development and manufacturing organization.

The German pharmaceuticals-and-chemicals company didn't disclose financial details for the transaction.

"The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases," Merck KGaA Chief Executive Stefan Oschmann said.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

January 07, 2021 04:35 ET (09:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Merck KGaA (PK) Charts.